[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [ACTIVE] · [BUSINESS]

2 clusters · 3 sources · 14 days · First seen · Last updated

Telix Pharmaceuticals market performance

Overview

Telix Pharmaceuticals, an Australian biotech company specializing in radiopharmaceuticals for cancer detection and treatment, has demonstrated significant market growth. By early September 2026, the company’s shares had nearly doubled since February, reaching $16.44. This growth follows a 22% year-on-year revenue increase to US$477 million and a 146% rise in adjusted EBITDA to US$52 million. The company has reaffirmed its FY26 revenue guidance of over US$1 billion.

In subsequent market activity, Telix is noted as a profitable, commercial-stage biotech with a market capitalization of $6.03 billion, currently conducting over 20 global clinical trials. It stands in contrast to other medical technology firms like 4DMedical Ltd, which focuses on respiratory imaging software but has not yet reached profitability.

Entities

Telix Pharmaceuticals Ltd · ASX · Wells Fargo & Company · MaxLinear, Inc. · Northland Securities

Timeline

  1. 5 days ago

    [BUSINESS] 2 sources
    MaxLinear and Australian med-tech firms see market activity

    MaxLinear shares rose over 5% amid mixed analyst ratings, while Australian med-tech firms 4DMedical and Telix Pharmaceuticals show divergent growth and profitability paths.

  2. 19 days ago

    [BUSINESS] 2 sources
    Australian market update: Telix Pharmaceuticals shares surge

    Telix Pharmaceuticals shares have nearly doubled since February amid strong revenue growth, while Telstra and Mineral Resources report varying performance in the Australian market.

Sources

fool.com.au · raskmedia.com.au · stocknews.com